Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

Publisher: La Merie Publishing
Pages: 16
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0150
Release Date: September of 2015

100.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for treatment of psoriasis and other inflammatory diseases as of September 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides a compilation of active products and projects on the market or in research and development as specific IL-23 or IL-12/23 (p40) antagonists as well as dual target IL-23 antagonists for treatment of immunologic diseases. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

 

Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists

Table of Contents

  • IL-12/23 (p40) Antagonists
  • Selective IL-23 Antagonists
  • Dual Target IL-23 Antagonists
  • Corporate IL-23 & IL-12/23 R&D Portfolios

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top